Xinxinli Blue Squares

USA300: multiple imports
and decline
Patrícia Martins Simões, PhD
Hospices Civils de Lyon, CIRI-INSERM U1111, University of Lyon,
National Reference Center for Staphylococci
Community Acquired (CA-)MRSA: historical clones
Western Australia,
USA400
European clone
USA300 clone
Taiwan clone
South West Pacific
clone
Global distribution of CA-MRSA (ST)
Deleo et al. Lancet (2010)
Dotted lines indicated = possible route of dissemination.
+, PVL-positive; −, PVL-negative; ±, combination of PVL-positive and PVL-negative strains isolated from the region.
Historical pandemic CA-MRSA are from distinct clonal lineages
CA-MRSA: USA300 clone
USA300 clone
1. skin and soft tissues infections (SSTIs) ++ in the early
2000's
USA300 clone
2. Prevalence > 50% in the US
3. PVL+ , MSLT ST8 , spa t008, sek, seq, SCCmec IV
4. PFGE typing : USA300 clone
Deleo et al. Lancet (2010)
CA-MRSA: pandemic USA300 clone
USA300 clone
1. skin and soft tissues infections (SSTIs) ++ in the early
2000's
2. Prevalence > 50% in the US
USA300
clone
3. PVL+ , MSLT ST8 , spa t008, sek, seq, SCCmec IV
4. PFGE typing : USA300 clone
Deleo et al. Lancet (2010)
Nimmo CMI (2014)
USA300 pandemic clone: multiple reports of its presence worldwide
USA300 CA-MRSA clone: what makes it special?
USA300 clone
1. skin and soft tissues infections (SSTIs) ++ in the early
2000's
USA300
clone
2. Prevalence > 50% in the US
3. PVL+ , MSLT ST8 , spa t008, sek, seq, SCCmec IV
4. PFGE typing : USA300 clone
Deleo et al. Lancet (2010)
5. Transmission ++ : arginine catabolic mobile element
(ACME) with arcABCD and speG → fitness
advantage/survival (human skin acid environment)
Thurlow et al. Cell Host and Microbes (2013)
arc protects from organic
acids
arc diverts L-arginine from
NO production
speG confers resistance
to toxic polyamines
USA300 CA-MRSA clone: what makes it special?
USA300 clone
1. skin and soft tissues infections (SSTIs) ++ in the early
2000's
2. Prevalence > 50% in the US
USA300
clone
3. PVL+ , MSLT ST8 , spa t008, sek, seq, SCCmec IV
4. PFGE typing : USA300 clone
5. Transmission ++ : arginine catabolic mobile element
(ACME) with arcABCD and speG → fitness
advantage/survival (human skin acid environment)
Deleo et al. Lancet (2010)
BUT the PFGE USA300 encompasses multiple “variants”: Canada,
USA, South America ...
USA300 CA-MRSA clone: what makes it special?
Planet et al. JID (2015)
Planet et al. JID (2016)
USA300 clone : at least 2 “variants” with a parallel evolution in the
American continent since 1980's (ACME not conserved but copB yes)
USA300 CA-MRSA clone: a pandemic in evolution
Nimmo CMI (2014)
Is the “USA300 clone” in an inter-continental
expansion phase?
USA300 CA-MRSA: the European continent
USA300 clone
Stegger et al. MBio (2014)
European Continent:
Köck Euro Surv. (2010)
Grundmann et al.Plos Med. (2010)
Brauner et al. Eur J Clin Microbiol Infect Dis. (2013)
Rolo et al.Plos One (2012)
Von Dach et al. JID (2016)
The most prevalent CA-MRSA in Europe: ST80-IV, pvl+
ST80-IV, pvl+ is starting to decline and co-exists with other CA-MRSA at low prevalences
Reports of USA300-NA in multiple countries has been increasing with local epidemics and multiple imports
USA300 in Europe: is it replacing the European clone ST80?
USA300 CA-MRSA: a French snapshot of 14 years
Genome wide comparison:
67 USA300 CA-MRSA strains reported in the last
decade (2000-2014)
431 ST8 MSSA and MRSA strains from the US
[Uhleman et al. PNAS (2014) + Tewhey et al. BMC Genomics
(2012)]
USA300 CA-MRSA: a French snapshot of 14 years
Genome wide comparison:
67 USA300 CA-MRSA strains reported in the last
decade (2000-2014)
431 ST8 MSSA and MRSA strains from the US
[Uhleman et al. PNAS (2014) + Tewhey et al. BMC Genomics
(2012)]
Red branches = US USA300-NA genomes
Blue branches = FR USA300-NA genomes
Strains isolated in France (blue) in the last
decade are interleaved with USA300-NA strains
from US (red)
USA300 clone in France: multiple introductions of USA300-NA lineage
in the last decade as early as the onset of this lineage
USA300 CA-MRSA: a French snapshot of 14 years
Genome wide comparison:
28 USA300 CA-MRSA strains reported between
2013-2014
Outbreak ?
USA300 clone in France: multiple introductions of USA300-NA lineage
in the last decade as early as the onset of this lineage
USA300 CA-MRSA: a French snapshot of 14 years
Genome wide comparison:
28 USA300 CA-MRSA strains reported
between 2013-2014
2 outbreaks from a same subclonal lineage of
USA300-NA
Same lineage was also responsible for
sporadic cases scattered in French territor
Dating froman introduction event occurring
~1998
USA300 clone in France: some introductions of the USA300-NA MRSA
clone can be successful but to a limited extent
USA300 CA-MRSA: a French snapshot of 14 years
Genome wide comparison:
67 USA300 CA-MRSA strains reported in the last
decade (2000-2014)
431 ST8 MSSA and MRSA strains from the US
[Uhleman et al. PNAS (2014) + Tewhey et al. BMC Genomics
(2012)]
Bayesian Skyline plot = inference of
population dynamics using coalescence
theory and estimation of effective population
sizes
Rise of USA300-NA: around 1996 with the acquisition of ACME and SCCmec
Second weaker expansion of USA300-NA lineage coincides with Fluoroquinolone resistance
Apparent decline of the USA300-NA lineage after 2008
USA300 CA-MRSA: a French snapshot of 14 years
Genome wide comparison:
67 USA300 CA-MRSA strains reported in the last
decade (2000-2014)
431 ST8 MSSA and MRSA strains from the US
[Uhleman et al. PNAS (2014) + Tewhey et al. BMC Genomics
(2012)]
Bayesian Skyline plot = inference of
population dynamics using coalescence
theory and estimation of effective population
sizes
Rise of USA300-NA: around 1996 with the acquisition of ACME and SCCmec
Second weaker expansion of USA300-NA lineage coincides with Fluoroquinolone resistance
Apparent decline of the USA300-NA lineage after 2008
USA300 clone: USA300-NA lineage seems to be in the decline phase
USA300 CA-MRSA: success in the European continent
CONCLUSION(S)
●
●
●
USA300-NA does not seem to have a “higher intrinsic” success than
the ST80 European clone
USA300 lineages show a trend to multiple introductions in Europe with
a failure to spread an establish endemic transmissions
USA300-NA CA-MRSA lineage seems to be in decline … WHY ?
Competition? Selection? Random Stochastic processes?
Glaser et al. Mbio (2016)
Von Dach et al. JID (2016)
Toleman et al. JID (2016)
CA-MRSAs: Pending Questions
●
●
●
●
What are the driving forces for the simultaneous worldwide
emergence of CA-MRSA clones?
Does the PVL acquisition play(ed) an advantageous evolutionary
role?
Why the large success of USA300-NA in the US?
Why the predicted decline of CA-MRSAs (ST80 and USA300-NA)?
Glaser et al. Mbio (2016)
Stegger et al. Mbio (2014)
CA-MRSA: Pending Questions
Some answers ...
Claude-Alexandre GUSTAVE
Dr. Anne TRISTAN
CA-MRSA USA300: Expansion and Virulence
Do expanding phases associate with increased expression of virulence
factors?
Approach:
qRT-PCR of virulence associated genes from the USA300 ancestral and derived lineages
Derived ACME +
FluorR
Ancestral ACME FluorS
Derived ACME +
FluorS
CA-MRSA USA300: Expansion and Virulence
Do expanding phases associate with increased expression of virulence
factors?
RNAIII
LukS-PVL
hla
HlgC
psmα
No significant difference in virulence genes expression between the
USA300 ancestral and derived USA300-NA strains
CA-MRSA USA300: Expansion and Fitness
Do expanding phases associate with increased fitness?
Approach:
1. assessment of doubling time (BHI, 24h)
2. competitive fitness in vitro (qRT-PCR for ACME and CGG + ATB for Fluor)
Derived ACME +
FluorR
Ancestral ACME FluorS
Derived ACME +
FluorS
CA-MRSA USA300: Expansion and Fitness
Do expanding phases associate with increased fitness?
Doubling Time and the acquisition of the ACME element
Ancestral ACME FluorS
Derived ACME +
FluorS
Doubling time (min)
30
***
28
26
24
***
or
S
or
S
AC
M
E-
Fl
u
Fl
u
E+
AC
M
AC
M
E+
Fl
u
or
S
22
Acquisition of ACME may be related to a decreased doubling time
between ancestral USA300 and derivate USA300-NA lineage
CA-MRSA USA300: Expansion and Fitness
Do expanding phases associate with increased fitness?
Doubling Time and the acquisition of Fluoroquinolones resistance
Derived ACME +
FluorR
Doubling time (min)
Ancestral ACME FluorS
30
***
28
26
24
***
or
R
Fl
u
or
S
AC
M
E+
Fl
u
E+
AC
M
AC
M
E+
Fl
u
or
S
22
Resistance to fluoroquinolones increased the doubling time between
derivate USA300-NA lineages
CA-MRSA USA300: Expansion and Fitness
Do expanding phases associate with increased fitness?
Competitive fitness in vitro of ACME- and ACME+ USA300 lineages
Ancestral ACME FluorS
Derived ACME +
FluorS
14
20
ACME acquisition seems to increase the fitness of the derived USA30NA lineage
CA-MRSA USA300: Expansion and Fitness
Do expanding phases associate with increased fitness?
Competitive fitness in vitro of USA300 derived lineages FluorS and FluorR
Derived ACME +
FluorR
Derived ACME +
FluorS
No ATB pressure
Acquisition of Fluoroquinolones resistance seems to be a mutation with a
deleterious fitness cost on the USA300-NA lineage
CA-MRSA USA300: Expansion and Fitness
Do expanding phases associate with increased fitness?
Competitive fitness in vitro of USA300 derived lineages FluorS and FluorR
Derived ACME +
FluorR
¼ MIC
Derived ACME +
FluorS
1/32
With ATB pressure (MIC = 0,38 µg/mL)
Acquisition of Fluoroquinolones resistance seems to confer an increased
fitness even at very low sub-inhibitory ATB concentrations
MIC
CA-MRSA USA300: Fitness and Virulence
CONCLUSION(S)
●
●
●
Expression of core-genome encoded virulence genes do not seem to
play a role in the USA300-NA CA-MRSA clone success
Acquisition of the ACME element seems to have been a driving force to
the USA300-NA CA-MRSA clone success
Acquisition of a Fluoroquinolones resistance is costly and slightly
deleterious without ATB pressure BUT plays a pivotal role in the fitness
of the derived USA300-NA CA-MRSA lineage even at very low subinhibitory MICs
Thank you for your attention
CIRI Team “staphylococcal pathogenesis”
Philippe GLASER
Prof. François VANDENESCH
All colleagues at the CIRI's team
Thierry WIRTH
All the CNR Staph : ingeniers, biologists, technicians
USA300 paper
Michele BES
Dr. Anne TRISTAN
Prof. Frederic LAURENT
Prof. Jerome ETIENNE
Claude-Alexandre
GUSTAVE
All the colleagues at the CX Rouss (HCL)